SAB-142 Phase 1 Data Shows C-Peptide Preservation in Type 1 Diabetes Patients

summarizeSummary

SAB Biotherapeutics reported encouraging Phase 1 data for SAB-142, showing C-peptide preservation in Type 1 Diabetes patients, supporting its disease-modifying potential.

check_boxKey Events

• Positive Phase 1 Data for SAB-142

  Additional data from the Phase 1 HUMAN trial showed SAB-142 treated participants (n=4) had no decrease in C-peptide levels at Day 120 compared to baseline, while the placebo participant showed a decrease.

• C-Peptide Preservation Observed

  The data indicates early signals of C-peptide preservation, consistent with the anticipated mechanism of action for SAB-142 in adult patients with established Type 1 Diabetes.

• Supports Phase 2b Advancement

  These findings further support the advancement of SAB-142 into the registrational Phase 2b SAFEGUARD trial, which was previously announced in the 10-K filed yesterday.

auto_awesomeAnalysis

SAB Biotherapeutics announced additional positive Phase 1 data for its lead candidate, SAB-142, in adult patients with established Type 1 Diabetes. The data demonstrated early signals of C-peptide preservation, a key indicator of beta cell function, which aligns with the drug's anticipated mechanism of action. This positive clinical update provides further validation for SAB-142 as it progresses into a registrational Phase 2b trial, reinforcing investor confidence in the program's potential to modify the course of T1D.